---
figid: PMC8454558__gr5
figtitle: Acquired resistance to third-generation EGFR-TKIs and emerging next-generation
  EGFR inhibitors
organisms:
- NA
pmcid: PMC8454558
filename: gr5.jpg
figlink: /pmc/articles/PMC8454558/figure/fig5/
number: F5
caption: EGFR-independent mechanisms of resistance to third-generation EGFR-TKIs(A)
  Activation of downstream EGFR signaling pathways. NRAS mutation, KRAS mutation,
  BRAF mutation, MEK1 mutation, deletion of NF1, or amplification of the CRKL gene
  sustains the activation of the MAPK/ERK signaling pathway. Deletion of the PTEN
  or PIK3CA mutation results in constitutive activation of the PI3K/AKT signaling
  pathway.(B) Oncogene fusions trigger sustained activation of survival-related signaling
  pathways.(C–G) Amplification of tyrosine kinase receptors including MET (C), HER2/3
  (D), IGF1R (E), AXL (F), and FGFR1 (G).(H) Alteration of cell-cycle-related genes.(I)
  Aberrant phosphorylation of ACK1 enhances the activation of the AKT signaling pathway,
  leading to decreased BIM levels.(J) Increased nuclear translocation of YAP upregulates
  the expression of FOXM1, which promotes the expression of SAC members.(K) Epithelial-mesenchymal
  transition (EMT).(L) Transformation from NSCLC to SCLC.
papertitle: Acquired resistance to third-generation EGFR-TKIs and emerging next-generation
  EGFR inhibitors.
reftext: Xiaojing Du, et al. Innovation (Camb). 2021 May 28;2(2):100103.
year: '2021'
doi: 10.1016/j.xinn.2021.100103
journal_title: The Innovation
journal_nlm_ta: Innovation (Camb)
publisher_name: Elsevier
keywords: Cancer | targeted therapy | EGFR inhibitors | drug resistance | mutations
  | chemoresistance mechanisms | surmounting chemoresistance
automl_pathway: 0.9332592
figid_alias: PMC8454558__F5
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8454558__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8454558__gr5.html
  '@type': Dataset
  description: EGFR-independent mechanisms of resistance to third-generation EGFR-TKIs(A)
    Activation of downstream EGFR signaling pathways. NRAS mutation, KRAS mutation,
    BRAF mutation, MEK1 mutation, deletion of NF1, or amplification of the CRKL gene
    sustains the activation of the MAPK/ERK signaling pathway. Deletion of the PTEN
    or PIK3CA mutation results in constitutive activation of the PI3K/AKT signaling
    pathway.(B) Oncogene fusions trigger sustained activation of survival-related
    signaling pathways.(C–G) Amplification of tyrosine kinase receptors including
    MET (C), HER2/3 (D), IGF1R (E), AXL (F), and FGFR1 (G).(H) Alteration of cell-cycle-related
    genes.(I) Aberrant phosphorylation of ACK1 enhances the activation of the AKT
    signaling pathway, leading to decreased BIM levels.(J) Increased nuclear translocation
    of YAP upregulates the expression of FOXM1, which promotes the expression of SAC
    members.(K) Epithelial-mesenchymal transition (EMT).(L) Transformation from NSCLC
    to SCLC.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HGF
  - IL6
  - SOS1
  - YAP1
  - ITK
  - SLC22A3
  - XYLT2
  - SOS2
  - CRKL
  - FOXM1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - GRB2
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - AURKA
  - AURKB
  - PLK1
  - EGF
  - GAB1
  - PIGU
  - SRC
  - FGR
  - FYN
  - YES1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - BCL2
  - MTOR
  - BCL2L11
  - SCLC1
  - GAS6
  - TNK2
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - CDK4
  - CDKN2A
---
